Valuation: Steminent Biotherapeutics Inc.

Market Cap 6.3B 198M 169M 159M 145M 273M 18.83B 276M 1.87B 728M 9.5B 742M 725M 31.46B P/E 2024
-8.1x
P/E 2025 -20.4x
Enterprise Value 5.88B 184M 158M 148M 135M 255M 17.56B 257M 1.74B 679M 8.86B 692M 676M 29.34B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
58.85%
Yield 2024 *
-
Yield 2025 -
1 day+0.26%
1 week-1.88%
Current month-1.01%
1 month+0.77%
3 months+8.61%
6 months-11.94%
Current year+30.12%
1 week 75.9
Extreme 75.9
80
1 month 68
Extreme 68
82.8
Current year 51.4
Extreme 51.4
95.6
1 year 37.85
Extreme 37.85
95.6
3 years 15.25
Extreme 15.25
95.6
5 years 15.25
Extreme 15.25
95.6
10 years 15.25
Extreme 15.25
95.6
Manager TitleAgeSince
Chief Executive Officer - 2018-11-25
Director of Finance/CFO - 2021-09-14
Investor Relations Contact - 2023-09-30
Director TitleAgeSince
Director/Board Member 54 2021-12-07
Director/Board Member - 2020-09-14
Chairman - 2024-01-25
Change 5-day change 1-year change 3-year change Capi.($)
+0.26%-1.88%+64.98% - 197M
+1.02%+4.95%+3.67%+25.46% 51.21B
-0.09%-2.14%+492.60%+537.84% 45.35B
-0.32%+8.08%+37.97%+18.45% 42.84B
+1.18%+1.96%+21.95%+89.69% 42.29B
-2.27%-3.02%+14.22%+51.50% 32.15B
-0.96%+4.03%+31.55%+136.34% 17.31B
+0.41%+1.66% - - 16.55B
+1.12%+6.35%+11.00%+32.62% 14.84B
-0.31%+6.61%+81.37%+48.53% 14.25B
Average -0.01%+2.60%+84.37%+117.55% 27.7B
Weighted average by Cap. +0.03%+2.85%+105.29%+136.29%

Financials

2024 2025
Net sales - -
Net income -159M -4.98M -4.26M -4M -3.65M -6.89M -474M -6.96M -47.13M -18.35M -239M -18.68M -18.28M -793M -174M -5.46M -4.67M -4.38M -4M -7.55M -520M -7.63M -51.67M -20.11M -262M -20.48M -20.04M -869M
Net Debt -153M -4.8M -4.12M -3.86M -3.52M -6.65M -458M -6.71M -45.49M -17.71M -231M -18.03M -17.64M -765M -426M -13.35M -11.44M -10.72M -9.79M -18.48M -1.27B -18.66M -126M -49.21M -642M -50.12M -49.03M -2.13B
Logo Steminent Biotherapeutics Inc.
Steminent Biotherapeutics Inc is a Taiwan-based trading company mainly engaged in the research and development of new stem cell drugs and the development of allogeneic mesenchymal stem cell technology platforms. The Company's main product is the new stem cell drug product Stemchymal. The new stem cell drug product Stemchymal is used to treat spinocerebellar ataxia, Huntington's disease, acute ischemic stroke, acute inflammatory indications and other diseases.
Employees
-
Date Price Change Volume
26-08-25 NT$78.20 +0.26% 758,470
26-08-24 NT$78.00 -1.14% 487,197
26-08-21 NT$78.90 -0.13% 235,469
26-08-20 NT$79.00 -0.50% 298,264
26-08-19 NT$79.40 -0.38% 233,138
  1. Stock Market
  2. Stocks
  3. 7729 Stock